Atlas Trials

A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

Clinical trial NCT07052994 · WITHDRAWN

Trial details

NCT number
NCT07052994
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Pediatric Acute Leukemia
Start date
2026-05-21
Primary completion
2026-05-21
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.